KaloCyte, Inc.

KaloCyte is developing ErythroMer, a bio-engineered artificial red blood cell substitute for treating severe blood loss when stored blood is unavailable.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Baltimore, MD, USA
  • Currency USD
  • Founded March 2016
  • Employees 9
  • Incorporation Type C-corp
  • Website kalocyte.com

Company Summary

KaloCyte is a pre-clinical biotech startup company developing ErythroMer, an artificial red blood cell (RBC) substitute that can be freeze-dried for long-term storage and used as a universal option for treatment of severe bleeding by EMS or battlefield medics when stored blood is unavailable or in short supply. KaloCyte, is supported by $14M of grant awards (DARPA, NIH) and $5M of investor funding raised to date.

Team

Advisors

  • Eric Clarke
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free